Researchers at the Garvan institute have published findings revealing a promising new therapeutic target to slow down or inhibit metastasis in pancreatic cancer. The study identified a metabolic signaling molecule involved in facilitating the spread of the disease to...

Prof Paul Timpson, head of the Invasion and Metastasis Lab, Professor Thomas Cox and Dr Brooke Pereira of the Garvan Institute of Medical Research were awarded funding from the Cancer Council to continue research into advancing treatment options for pancreatic cancer....

Professor Anthony Gill was honoured as the winner of the 2023 Outstanding Cancer Researcher of the Year for his significant contributions to the field of cancer diagnosis and pathology. The Premier’s Awards for Outstanding Cancer Research is the highest accolade for...

November is recognised as World Pancreatic Cancer Awareness Month where we take time to raise awareness of the disease. The theme for this year is 'Hello Pancreas', an engaging way of helping people to become more aware of the pancreas organ, it's function in the body...

Researchers at the Garvan Institute have developed a novel way to monitor drug response and resistance in pancreatic cancer, utilizing a mouse model that allows for the real time visualisation of the effect of drug treatment within tumours. The team at the Garvan...

2022 was another year of facing and overcoming challenges for people around the world. As we move into a new year, it is a good time to reflect on achievements and accomplishments. Throughout the year, the APGI has continued to support Pancreatic Cancer research...

In recognition of Pancreatic Cancer Awareness Month, this November iconic buildings over Australia will light up purple to raise awareness for the disease and to celebrate and honour survivors and loved ones. Pancreatic cancer is the third leading cause of cancer...

A new clinical trial for people with advanced pancreatic cancer, has now commenced in Australia. The trial led by Amplia Therapeutics, in collaboration with Professor Paul Timpson from the Invasion and Metastasis Lab at The Garvan Institute of Medical Research, will...

Pancreatic cancer is one of the most aggressive cancers and five-year survival rates are just 10%. A very small number of patients live longer, with less than 2% surviving more than 10 years after diagnosis. Researchers have been working to understand how this cancer...

The Avner Australian Pancreatic Cancer Matrix Atlas group (APMA) will investigate a potential new way to improve immunotherapy outcomes for patients with pancreatic cancer using a class of drug that can reduce the metabolic rewiring of the cancer cells thanks to a...